DRKS00022378已完成未知
ast Year of Life Study Cologne (LYOL-C II): Modelling and evaluation of a minimally invasive two-sided intervention to deliver patient-centered care in hospitals - LYOL-C II
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •- written consent has been obtained,
- •- Full command of the German language
- •- they are informed that his or her disease is not curable and has progressed and that the probability of surviving the disease is low
- •- Surprise Question answered with no” (and SPICT criteria are met)
排除标准
- •> Person refuses to participate
- •> No sufficient knowledge of German
- •> The patient is not able to give written informed consent to participate in the study.
- •> The patient is not informed that his/her disease is not curable and advanced and that the probability of surviving the disease is low.
- •> Control group: SPICT criteria not met.
- •> Intervention group: prognosis of 12 months (Surprise Question answered with yes)
- •> No consent / or consent later withdrawn
研究者
相似试验
进行中（未招募）
1 期
A study in T-ALL/T-LBL PatientsT-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)EUCTR2014-005024-10-SEEli Lilly and Company36
进行中（未招募）
1 期
A study in T-ALL/T-LBL PatientsT-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)EUCTR2014-005024-10-DEEli Lilly and Company36
进行中（未招募）
1 期
A study in T-ALL/T-LBL PatientsEUCTR2014-005024-10-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER36
已完成
不适用
A prospective observational study investigating clinicopathological and molecular biological features in FGFR2-fusion positive biliary tract cancerbilary tract cancerJPRN-UMIN000014767Exploratory Oncology Research & Clinical Trial Center500
进行中（未招募）
不适用
A combined phase 1 and 2 study investigating the combination of RAD001 and erlotinib in patients with advanced NSCLC previously treated only with chemotherapy - N/AEUCTR2004-003017-16-DKovartis Pharma Services AG180